Abstract 2349
Background
Previous clinical trials demonstrated that alectinib (ALEC) produced fewer adverse events compared to crizotinib (CRZ). Data regarding adverse events (AE) in clinical practice, however, is limited. We reviewed ALK-rearranged NSCLC patients treated with crizotinib or alectinib in institutions of the West Japan Oncology Group, and the safety of CRZ and ALEC were evaluated using the real-world data.
Methods
We reviewed the clinical data of ALK-rearranged NSCLC patients who received CRZ or ALEC between May 2012 and Dec 2016. Patients were divided into two groups, the CRZ, or the ALEC group. To evaluate the safety of each ALK-inhibitor, we compared the AEs between the CRZ and the ALEC groups.
Results
Of 864 patients enrolled from 61 institutions, 840 patients were analyzed. Median age was 61 (range, 20-94); 56% were female; and 95% had adenocarcinoma. There was no significant difference in the frequencies of ILD, renal dysfunction, and digestive dysfunction between the CRZ and the ALEC groups.(p = 0.905, p = 0.7208, p = 0.1735) Meanwhile, liver dysfunction was significantly more frequent in the CRZ group compared to the ALEC group.(50.7% in CRZ group vs. 29.1% in ALEC group, p = 0.0313) In adverse events of grade 3 or more, liver dysfunction remained significantly different in frequency between the two groups.(13.3% in CRZ vs. 3.9% in ALEC, p < 0.0001) Discontinuation due to adverse event was shown to be in 21.1% in the CRZ group, and 6.9% in the ALEC group.(p = 0.0656) Seventy-nine patients received alectinib therapy after the discontinuation of crizotinib due to an adverse event, with progression-free survival (PFS) of 24.8 months.
Conclusions
In clinical practice, the patients treated with CRZ exhibited a trend to discontinue CRZ at a higher rate due to AE compared to the ALEC group. The PFS of patients treated with ALEC, even in the patients who experience AE due to CRZ, was more than 2 years.
Clinical trial identification
UMIN000028605.
Editorial acknowledgement
Legal entity responsible for the study
Nobuyuki Yamamoto.
Funding
Pfizer.
Disclosure
K. Ito: Honoraria (self): Pfizer; Honoraria (self), Research grant / Funding (institution): Boehringer Ingelheim; Speaker Bureau / Expert testimony: Chugai; Honoraria (self): Eli Lilly; Honoraria (self): MSD; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Kyorin; Research grant / Funding (institution): Daiichi-Sankyo. T. Yamanaka: Honoraria (self), Research grant / Funding (self): Takeda; Honoraria (self): Chugai; Honoraria (self), Research grant / Funding (self): Taiho; Honoraria (self): Boehringer Ingelheim; Advisory / Consultancy: Giiead Sciences; Advisory / Consultancy: Bayer. D. Fujimoto: Honoraria (self), Research grant / Funding (self): AstraZeneca; Honoraria (self): Ono Pharmaceutical; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Taiho Pharmaceutical Co; Honoraria (self): Chugai Pharmaceutical Co; Honoraria (self): MSD KK; Honoraria (self): Boehringer Ingelheim Japan Inc; Honoraria (self): Eli Lilly Japan KK,. M. Mori: Honoraria (institution), Speaker Bureau / Expert testimony: Chugai. H. Tanaka: Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (institution): Eli Lilly; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Taiho pharmaceuticals; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Novartis; Honoraria (self), Research grant / Funding (institution): Ono pharmaceuticals; Honoraria (self), Research grant / Funding (institution): Chugai pharmaceuticals; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Takeda pharmaceuticals; Research grant / Funding (institution): Merck Serono. S. Teraoka: Honoraria (self): Chugai Pharmaceutical. O. Hataji: Honoraria (self): Chugai; Honoraria (self): Pfizer; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Boerhringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Daiichi-Sankyo; Honoraria (self), Research grant / Funding (institution): Kyorin; Honoraria (self): Eli Lilly. A. Bessho: Honoraria (self), Speaker Bureau / Expert testimony: Chugai Pharmaceutical Co., Ltd.; Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (institution): Pfizer Japan Inc. A. Kubo: Honoraria (self), Research grant / Funding (self): Boehringer Ingerheim; Honoraria (self), Research grant / Funding (self): Chugai; Honoraria (self), Research grant / Funding (self): Eli Lilly; Honoraria (self): MSD; Honoraria (self), Research grant / Funding (self): Novartis; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (self): Ono Pharma. K. Nakagawa: Honoraria (self), Advisory / Consultancy: Astellas Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Takeda Pharmaceutical; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Chugai; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Eli Lilly; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo; Honoraria (self), Research grant / Funding (institution): Novartis Pharma; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Pfizer Japan; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb Company; Honoraria (self): KYORIN Pharmaceutical; Honoraria (self): MEDICUS SHUPPAN,Publishers; Honoraria (self): Thermo Fisher Scientific K.K; Honoraria (self): Nichi-Iko Pharmaceutical ; Honoraria (self): Hisamitsu Pharmaceutical; Research grant / Funding (institution): Eisai Co; Research grant / Funding (institution): PAREXEL International Corp. N. Yamamoto: Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Chugai. All other authors have declared no conflicts of interest.
Resources from the same session
681 - Significance of the red blood cell distribution width in resected pathological stage I non-small cell lung cancer
Presenter: Gouji Toyokawa
Session: Poster Display session 1
Resources:
Abstract
3336 - Survival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR)
Presenter: Rolf A. Stahel
Session: Poster Display session 1
Resources:
Abstract
2204 - NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
Presenter: María Guirado
Session: Poster Display session 1
Resources:
Abstract
1446 - A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators set by principle component analysis
Presenter: Bo Cheng
Session: Poster Display session 1
Resources:
Abstract
1788 - Prognostic and predictive value of 18F-PET/CT on the response to treatment in locally advanced non-small cell lung cancer (NSCLC)
Presenter: Cristina Alfaro Autor
Session: Poster Display session 1
Resources:
Abstract
2299 - Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non small cell lung cancer
Presenter: Abdurrahman Işıkdoğan
Session: Poster Display session 1
Resources:
Abstract
4211 - Predicting the first failure pattern in patients with inoperable local advanced non-small cell lung cancer (LA-NSCLC) receiving definitive chemoradiotherapy: Establishment and internal validation of a nomogram based on the clinicopathological factors
Presenter: Xueru Zhu
Session: Poster Display session 1
Resources:
Abstract
1550 - Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) pre and post chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC)
Presenter: Vicente Palomar Abril
Session: Poster Display session 1
Resources:
Abstract
2345 - Meta-analysis evaluating neutropenia incidence with EGFR inhibitors and chemotherapy in patients with NSCLC
Presenter: Bernardo Rapoport
Session: Poster Display session 1
Resources:
Abstract
3747 - Effector CD4+ T-cell induction by thoracic radiotherapy for patients with NSCLC
Presenter: Yu Miura
Session: Poster Display session 1
Resources:
Abstract